ACCUSTEM SCIENCES INC Financials
This page shows ACCUSTEM SCIENCES INC (ACUT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AccuStem looks like a financing-dependent company where liabilities outran cost cuts, leaving operations unable to support the balance sheet.
Cash burn improved from$1.81M in FY2022 to$850K in FY2025, showing the loss rate eased. But current ratio fell to 0.01x while liabilities reached$4.95M , so lower burn has not translated into a healthier funding base; the company looks cheaper to run, but not self-sustaining.
FY2025’s operating cash outflow of
The expense mix looks overhead-heavy: SG&A was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of ACCUSTEM SCIENCES INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ACCUSTEM SCIENCES INC carries a low D/E ratio of -1.46, meaning only $-1.46 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.
ACCUSTEM SCIENCES INC's current ratio of 0.01 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
ACCUSTEM SCIENCES INC passes 1 of 9 financial strength tests. 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, ACCUSTEM SCIENCES INC generates $0.48 in operating cash flow (-$850K OCF vs -$1.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
ACCUSTEM SCIENCES INC's EBITDA was -$1.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
ACCUSTEM SCIENCES INC reported -$1.8M in net income in fiscal year 2025.
ACCUSTEM SCIENCES INC earned $-0.12 per diluted share (EPS) in fiscal year 2025. This represents an increase of 7.7% from the prior year.
Cash & Balance Sheet
ACCUSTEM SCIENCES INC held $14K in cash against $0 in long-term debt as of fiscal year 2025.
ACCUSTEM SCIENCES INC had 16M shares outstanding in fiscal year 2025. This represents an increase of 41.6% from the prior year.
Margins & Returns
Capital Allocation
ACCUSTEM SCIENCES INC invested $281K in research and development in fiscal year 2025. This represents an increase of 103.2% from the prior year.
ACUT Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $120K | N/A | $73K+20.8% | $60K+112.4% | $28K | N/A | $31K-24.8% | $42K |
| SG&A Expenses | $366K | N/A | $327K-4.1% | $341K-17.2% | $412K | N/A | $297K+25.5% | $236K |
| Operating Income | -$486K | N/A | -$400K+0.4% | -$401K+8.9% | -$440K | N/A | -$328K-18.0% | -$278K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$486K | N/A | -$400K+0.4% | -$401K+8.9% | -$440K | N/A | -$328K-18.0% | -$278K |
| EPS (Diluted) | $-0.03 | N/A | $-0.020.0% | $-0.02+33.3% | $-0.03 | N/A | $-0.03-50.0% | $-0.02 |
ACUT Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5M0.0% | $1.5M-1.5% | $1.6M-2.5% | $1.6M+4.1% | $1.6M+2949.3% | $51K-51.0% | $104K-25.7% | $140K |
| Current Assets | $50K+0.2% | $49K-96.9% | $1.6M-2.5% | $1.6M+4.1% | $1.6M+2974.3% | $50K-50.8% | $102K-25.4% | $137K |
| Cash & Equivalents | $12K-12.4% | $14K-3.2% | $14K-54.1% | $31K-13.9% | $36K+621.0% | $5K-86.4% | $37K-19.5% | $46K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.4M+9.5% | $5.0M+10.4% | $4.5M+8.1% | $4.1M+11.9% | $3.7M+10.2% | $3.4M+2.0% | $3.3M+9.0% | $3.0M |
| Current Liabilities | $5.4M+9.5% | $5.0M+10.4% | $4.5M+8.1% | $4.1M+11.9% | $3.7M+10.2% | $3.4M+2.0% | $3.3M+9.0% | $3.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.9M-13.8% | -$3.4M-16.9% | -$2.9M-14.8% | -$2.5M-17.5% | -$2.2M+34.9% | -$3.3M-3.7% | -$3.2M-10.7% | -$2.9M |
| Retained Earnings | -$10.3M-5.0% | -$9.8M-5.5% | -$9.3M-4.5% | -$8.9M-4.7% | -$8.5M-5.5% | -$8.0M-4.9% | -$7.7M-4.5% | -$7.3M |
ACUT Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$374K-1773.6% | $22K+103.7% | -$604K-2901.2% | $22K+107.4% | -$290K-70192.3% | $414+100.2% | -$218K-4.2% | -$209K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $372K+1732.1% | -$23K-103.9% | $587K+2306.9% | -$27K-108.3% | $322K+1090.9% | -$32K-115.5% | $209K-15.0% | $246K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ACUT Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -31.4% | N/A | -25.4%-0.5pp | -24.9%+3.5pp | -28.4% | N/A | -316.1%-116.9pp | -199.2% |
| Current Ratio | 0.010.0 | 0.01-0.3 | 0.35-0.0 | 0.39-0.0 | 0.42+0.4 | 0.01-0.0 | 0.03-0.0 | 0.05 |
| Debt-to-Equity | -1.40+0.1 | -1.46+0.1 | -1.54+0.1 | -1.64+0.1 | -1.72-0.7 | -1.02+0.0 | -1.03+0.0 | -1.05 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is ACCUSTEM SCIENCES INC profitable?
No, ACCUSTEM SCIENCES INC (ACUT) reported a net income of -$1.8M in fiscal year 2025.
What is ACCUSTEM SCIENCES INC's EBITDA?
ACCUSTEM SCIENCES INC (ACUT) had EBITDA of -$1.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ACCUSTEM SCIENCES INC's operating cash flow?
ACCUSTEM SCIENCES INC (ACUT) generated -$850K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are ACCUSTEM SCIENCES INC's total assets?
ACCUSTEM SCIENCES INC (ACUT) had $1.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does ACCUSTEM SCIENCES INC spend on research and development?
ACCUSTEM SCIENCES INC (ACUT) invested $281K in research and development during fiscal year 2025.
What is ACCUSTEM SCIENCES INC's current ratio?
ACCUSTEM SCIENCES INC (ACUT) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is ACCUSTEM SCIENCES INC's debt-to-equity ratio?
ACCUSTEM SCIENCES INC (ACUT) had a debt-to-equity ratio of -1.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ACCUSTEM SCIENCES INC's return on assets (ROA)?
ACCUSTEM SCIENCES INC (ACUT) had a return on assets of -113.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ACCUSTEM SCIENCES INC's cash runway?
Based on fiscal year 2025 data, ACCUSTEM SCIENCES INC (ACUT) had $14K in cash against an annual operating cash burn of $850K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is ACCUSTEM SCIENCES INC's debt-to-equity ratio negative or unusual?
ACCUSTEM SCIENCES INC (ACUT) has negative shareholder equity of -$3.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is ACCUSTEM SCIENCES INC's Piotroski F-Score?
ACCUSTEM SCIENCES INC (ACUT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ACCUSTEM SCIENCES INC's earnings high quality?
ACCUSTEM SCIENCES INC (ACUT) has an earnings quality ratio of 0.48x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is ACCUSTEM SCIENCES INC?
ACCUSTEM SCIENCES INC (ACUT) scores 13 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.